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doi:10.1Objective: Losartan potassium (INN losartan), an antihypertensive drug, has been shown to prevent thoracic aor-
tic aneurysm in Marfan syndrome through the inhibition of transforming growth factor b. Recently we reported
that doxycycline, a nonspecific inhibitor of matrix metalloproteinases 2 and 9, normalized aortic vasomotor
function and suppressed aneurysm growth. We hypothesized that a combination of losartan potassium and
doxycycline would offer better secondary prevention treatment than would single-drug therapy to manage
thoracic aortic aneurysm.
Methods: A well-characterized mouse model of Marfan syndrome (Fbn1C1039G/þ) was used. At 4 months of age,
when aneurysm had established, mice (n ¼ 15/group) were given doxycycline alone (0.24 g/L), losartan potas-
sium alone (0.6 g/L), or combined (0.12-g/L doxycycline and 0.3-g/L losartan potassium) in drinking water.
Littermate Fbn1þ/þmice served as control. Thoracic aortas at 6 and 9 months were studied.
Results: At 9 months, aortic diameter in untreated group was increased by 40% relative to control. Losartan
potassium or doxycycline reduced aortic diameter by 10% to 16% versus untreated aortas. Losartan potassium
and doxycycline combined completely prevented thoracic aortic aneurysm and improved elastic fiber organiza-
tion, also downregulating matrix metalloproteinases 2 and 9 and transforming growth factor b and normalizing
aortic contractile and relaxation functions to control values.
Conclusions: Neither losartan potassium nor doxycycline alone completely restored vascular integrity and cell
function when given during delayed treatment, indicating the importance of timed pharmacologic intervention.
Combined, however, they synergistically offered better aneurysm-suppressing effects than did single-drug
medication in the secondary prevention of thoracic aortic aneurysm. (J Thorac Cardiovasc Surg 2010;140:305-12)Supplemental material is available online.
Marfan syndrome is an autosomal dominant disorder of con-
nective tissue resulting from mutations in the gene encoding
fibrillin-1. Fibrillin-1 is a principal component of the extra-
cellular microfibrils, which are crucial for organizing
scaffold in the formation and maturation of elastic fibers.
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The Journal of Thoracic and Caaorta and cause microdissection, degeneration, and fibrosis
of the media in the aorta. Consequently, progressive thoracic
aortic aneurysm (TAA), dissection, and rupture account for
more than 90% of mortality in Marfan syndrome.1 Clinical
management of TAA in Marfan syndrome aims to decrease
the rate of aortic root dilatation and reduce the risk of dissec-
tion and rupture. b-Adrenoceptor blockade (atenolol,
propranolol hydrochloride [INN propranolol]) has been
advocated for preventive therapy.2 This treatment does
not, however, prevent attainment of important clinical end
points, including aortic regurgitation, surgery, aortic dissec-
tion, and death. b-Adrenoceptor blockade improves aortic
elasticity in patients with modest aortic dilatation, but no
benefit is observed in patients with marked dilatation.3,4
There is thus a need for the development of more specific
and effective pharmacologic strategies for the management
of TAA in Marfan syndrome.
Aortic aneurysm is characterized by impairment of vascu-
lar cell function, destruction of extracellular matrix integrity,
and deterioration of vessel wall mechanical properties. We
have previously demonstrated that the progression of TAA
in Marfan syndrome is associated with upregulation of ma-
trix metalloproteinases (MMPs)MMP-2 andMMP-9, which
is concomitant with extensive degeneration of elastic fibers,rdiovascular Surgery c Volume 140, Number 2 305
Abbreviations and Acronyms
MMP ¼ metalloproteinase
TAA ¼ thoracic aortic aneurysm
TGF-b ¼ transforming growth factor b
TIMP ¼ tissue inhibitor of metalloproteinase
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Dalterations in aortic mechanical properties, endothelial dys-
function, and reduction of smooth muscle contractility.5-7
Importantly, we have suggested that doxycycline, through
its inhibition of MMP-2 and MMP-9, offers better aneu-
rysm-suppressing properties than atenolol in the mouse
model of Marfan syndrome.5
Recent investigations have demonstrated that perturba-
tion of transforming growth factor b (TGF-b)/Smad2 signal-
ing contributes to the prominent clinical manifestations in
Marfan syndrome. Antagonizing TGF-b through TGF-
b–neutralizing antibodies or losartan potassium (INN losar-
tan), an angiotensin II type 1 receptor antagonist, has been
shown to prevent aortic elastic fiber degeneration, aortic
root dilatation, mitral valve prolapse, alveolar sepatation,
and skeletal muscle dysfunction in a mouse model of Marfan
syndrome.8,9 The prolonged administration of losartan po-
tassium as a pharmacologic strategy for the management
of TAA in patients with Marfan syndrome is therefore con-
sidered to have great potential. A multicenter, randomized,
clinical trial has been initiated for the comparison of the
effectiveness of losartan potassium and atenolol in patients
with Marfan syndrome.10
From the recent literature, it has become clear that both
TGF-b and MMP-2/MMP-9 signaling are crucial in mediat-
ing aortic pathogenesis in Marfan syndrome, and the poten-
tial cross talk between these signaling molecules has been
widely demonstrated.11-16 Overexpression of TGF-b and
the concomitant upregulation of various MMPs and tissue
inhibitors of metalloproteinase (TIMPs) have been sug-
gested to be associated with increased apoptosis, impaired
progenitor cell recruitment, and abnormal directional migra-
tion, all of which are likely to contribute to aneurysmal de-
velopment in Marfan syndrome.11,12 The combination of
losartan potassium and doxycycline is of great interest
because this combination, by downregulating MMPs and
TGF-b, may potentially provide synergistic benefits in the
management of TAA.
This study was designed to investigate the potential
synergistic effects of combining doxycycline and losartan
potassium in the secondary prevention of TAA in Marfan
syndrome. We have demonstrated that neither losartan
potassium nor doxycycline alone could completely restore
vascular integrity and cell function when given during the
delayed treatment, indicating the importance of timed phar-
macologic intervention; however, combined treatment with306 The Journal of Thoracic and Cardiovascular Surglosartan potassium and doxycycline effectively modified
the progression of TAA by downregulating MMP/TGF-b
activation, normalizing elastic fiber structure and aortic cel-
lular function, and, most importantly, reducing aneurysmal
size.MATERIALS AND METHODS
Experimental Animals and Tissue Preparation
Heterozygous (Fbn1C1039G/þ, the most common class of mutation inMar-
fan syndrome) mice were bred with wild-type mice (C57BL/6) to generate
control (Fbn1þ/þ) and Marfan mice, which were housed in the institutional
animal facility. All animal procedures were approved by the institutional
animal ethics board,5-8 and all animals received humane care in compliance
with the Guide for the Care and Use of Laboratory Animals (www.nap.edu/
catalog/5140.html).
Two major questions were addressed: (1) How effective are losartan
potassium and doxycycline in remedying TAA and vascular function
when given alone after pronounced aneurysm has developed (4 months of
age5-8)? (2) What, if any, are the synergistic aneurysm-suppressing effects
of combined therapy?
To highlight the synergistic relation between losartan potassium and
doxycycline, we used half the dosage used in the primary treatment5,8 in
the combined therapy. From preliminary experiments, we found that half
the dosage of either drug alone did not have a significant aneurysm-sup-
pressing effect and did not improve vasomotor function (data not shown).
Marfan mice starting at 4 months of age were left untreated or given losartan
potassium (0.6 g/L, n ¼ 30),8 doxycycline (0.24 g/L, n ¼ 30),5 or a combi-
nation of losartan potassium and doxycycline (0.3-g/L losartan potassium
plus 0.12-g/L doxycycline, n¼ 30) in drinking water, then humanely killed
at 6 or 9 months. Because doxycycline is light sensitive and only stable in
aqueous solution for 48 hours, the doxycycline-laced water was shielded
from all light and changed every other day, while the losartan potassium–
laced water was changed once a week.
Segments of ascending thoracic aorta (length, 1.2 mm), aortic arch (3
mm), and descending thoracic aorta (3 mm) were fixed for histologic anal-
ysis. A segment of aortic arch (1.8 mm) was used for the functional study
(ascending aorta was not used for functional study because of its short
length). The remaining aortic arch was flash-frozen for sample homogeniza-
tion and protein extraction.
Procedures for gelatinolytic zymography, Movat staining, isometric
force measurement Western immunoblotting, and aortic mechanical prop-
erty determination are provided in Appendix E1.
Statistics
Data are reported as mean  SEM. Statistical analysis and stress–strain
exponential curves were prepared with GraphPad Prism software (Graph-
Pad Software, Inc, San Diego, Calif). Comparisons were performed with
1-way analysis of variance (with Bonferroni post hoc analysis for multiple
comparisons).RESULTS
Thoracic Aortic Aneurysm
At 6 and 9 months of age, the ascending aorta was en-
larged by 40% in the untreated Marfan mice compared
with the age-matched controls. With losartan potassium
treatment, aortic diameter was increased by 25% at 6
months but not significantly increased at 9 months relative
to control. Aortic dilatation was significantly attenuated by
doxycycline at 6 months of age; at 9 months, the aortic diam-
eter in the doxycycline group was comparable to that in theery c August 2010
FIGURE 1. Average diameter thoracic aorta. A, Ascending; B, descend-
ing. Hatch mark indicates P< .05 versus age-matched control. Asterisk in-
dicates P<.05 versus age-matched untreated Marfan group. LOR, Losartan
potassium; DOX, doxycycline.
FIGURE 2. A, Averaged architecture score of aortic wall (n ¼ 7–10).
Three aortic segments from each mouse (9 months) were examined by 3 ob-
servers blinded to genotype and treatment. B, Breaking stress of thoracic
aorta. Hatch mark indicates P< .05 versus age-matched control. Asterisk
indicates P<.05 versus age-matched untreated Marfan group. LOR, Losar-
tan potassium; DOX, doxycycline.
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tan potassium prevented aortic dilatation throughout the life
span (Figure 1, A). There was descending thoracic aortic di-
latation in the untreated Marfan group, which was prevented
by both single and combined therapies (Figure 1, B).Elastic Fiber Structural Integrity
Compared with control, Marfan aortic elastic fibers ex-
hibited severe fragmentation, thinning, and disorganiza-
tion.5,6 Losartan potassium and doxycycline improved the
architecture, although breakage of elastic fibers was still ob-
served within the media. Areas of local thinning, or uneven
aortic wall thickness, were observed in the losartan potas-
sium group. The combination of losartan potassium and
doxycycline greatly improved the elastic fiber structure
and restored the wavy organization, which was indistin-
guishable from fibers in control specimens (Figures 2, A,
and 3).
To investigate the structural stability, we measured the
breaking stress, which represents the breakage of the elastic
fiber and smooth muscle association and at which the vessel
could no longer maintain the stable resting tension. At 6
months, the breaking stress was 33% lower in the untreated
Marfan aortas than in aortas from the control mice; the ease
of losing preservation of stable tension suggested structural
weakening in the untreated aorta. Losartan potassium,The Journal of Thoracic and Cadoxycycline, and the combination of losartan potassium
and doxycycline effectively improved breaking stress to
the control value. At 9 months, although control, untreated,
and losartan potassium–treated aortas showed similar break-
ing stresses, aortas treated with doxycycline and with com-
bination of doxycycline with losartan potassium slightly
but significantly increased breaking stress by 20% com-
pared with the untreated value (Figure 2, B).Expressions of MMP-2, MMP-9, and TGF-b/
Phosphorylated Smad2
Although doxycycline prevented the upregulation of ge-
latinolytic activities of MMP-2 and MMP-9 at 6 months of
age, pronounced enhancement of MMP activity at 9 months
was not prevented by doxycycline. Whereas losartan potas-
sium alone reduced the increasedMMP-2 andMMP-9 activ-
ities only at 9 months of age, in combination with
doxycycline it suppressed the MMP activation at both 6
and 9 months (Figure 4, A).
In the Western immunoblotting, the upregulation of
MMP-9/TIMP-1 ratio in the Marfan group at 9 months of
age was effectively prevented by losartan potassium both
alone and in combination with doxycycline. At 6 months,
the MMP-2/TIMP-2 ratio was significantly reduced byrdiovascular Surgery c Volume 140, Number 2 307
FIGURE 3. Integrity of elastic fibers examined on Movat-stained cross-sections of ascending thoracic aorta (ATA), arch, and descending thoracic aorta
(DTA) from control, Marfan, Marfan with losartan potassium (LOR),Marfan with doxycycline (DOX), and Marfan with both drugs at 9 months. Elastic fibers
are stained as black fibrils.
Acquired Cardiovascular Disease Yang et alA
C
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ment by 25% to 40% compared with the untreated group.
At 9 months, losartan potassium suppressed the increase308 The Journal of Thoracic and Cardiovascular Surgof MMP-2/TIMP-2 ratio in the Marfan aortas, and the com-
bination with doxycycline further reduced this ratio to 70%
of the control level (Figure 4, B).ery c August 2010
FIGURE 4. A, Representative gelatinolytic zymograms indicating activities of matrix metalloproteinases (MMPs) 2 and 9. B, Representative Western blots
showing protein expressions of matrix metalloproteinases 9 and 2, tissue inhibitors of metalloproteinase (TIMPs) 1 and 2, transforming growth factor b (TGF-
b), and phosphorylated Smad2 (p-Smad2) in aortic samples. Densitometric analysis shows ratios of expressions of matrix metalloproteinase 9/tissue inhibitor
of metalloproteinase 1 (C) and matrix metalloproteinase 2/tissue inhibitor of metalloproteinase 2 (D). Asterisk indicates P<.05 versus age-matched untreated
Marfan group. LOR, Losartan potassium; DOX, doxycycline.
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were in concordance with MMP-2 and MMP-9 levels.
Doxycycline inhibited the increased expression of TGF-b/
phosphorylated Smad2 at 6 months of age; however, this ex-
pression was elevated at 9 months. Losartan potassium alone
and in combination with doxycycline normalized the TGF-
b/phosphorylated Smad2 expression to the control level at
both 6 and 9 months of age (Figure 4, B).
Vasocontractile Function and Endothelial-Dependent
Relaxation
At 6 and 9 months, the depressed potassium chloride–in-
duced contraction in the Marfan aorta was normalized to the
control values with losartan potassium, doxycycline, and
combined treatment (Figure 5, A and B). The depressed
phenylephrine-stimulated contraction (in terms of both
maximum effect and negative logarithm of 50% effective
concentration values) in the untreated group at 9 monthsThe Journal of Thoracic and Cawas improved by losartan potassium alone and in combina-
tion with doxycycline (Figure 5, C and D).
The maximum effect of endothelium-dependent acetyl-
choline-induced relaxation was significantly improved by
doxycycline at 6 months of age, although the response re-
mained suppressed relative to the control value. Losartan
potassium exhibited a trend toward improvement in relax-
ation that was comparable to the response of doxycycline,
although it did not reach a significant difference from the
untreated group (Figure 5, E). The negative logarithm of
50% effective concentration values of acetylcholine
response was normalized to the control level by all treat-
ments at 6 and 9 months (data not shown). At 9 months,
control and untreated groups exhibited similar relaxation
responses; however, doxycycline both alone and in
combination with losartan potassium greatly enhanced
the relaxation response, to 72% and 80%, respectively
(Figure 5, F).rdiovascular Surgery c Volume 140, Number 2 309
FIGURE 5. Contraction induced by 60-mmol/L potassium chloride (KCl, A and B). A, At 6 months; B, at 9 months. Contraction stimulated by phenyleph-
rine (PE) at 9 months of age (C and D). C, Maximal response (Emax); D, Negative logarithm of 50% effective concentration (pEC50). Maximal relaxation
induced by acetylcholine (ACh, E and F). E, At 6 months; F, at 9 months. Asterisk indicates P<.05 versus age-matched untreated Marfan group. LOR, Los-
artan potassium; DOX, doxycycline.
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DDISCUSSION
Despite major advances in the medical and surgical man-
agement of Marfan syndrome, morbidity persists. Existing
medical therapies, such as b-adrenoceptor blockers and cal-
cium-channel blockers, reduce hemodynamic stress on the
aorta2 but do not target the pathogenetic basis ofMarfan syn-
drome. Recent publications have demonstrated that defi-
ciency of fibrillin-1–containing microfibrils results in
excessive TGF-b activation in many tissues that are altered
in Marfan syndrome. TGF-b antagonism by losartan potas-
sium has been shown to prevent aortic root dilatation, mitral
valve prolapse, lung disease, and skeletal muscle dysfunc-
tion in a mouse model of Marfan syndrome.8,9 We have
also demonstrated the benefits of doxycycline, through its
inhibition on MMP-2 and MMP-9, in preventing TAA,
preserving elastic fiber integrity, and normalizing aortic
vasomotor function and mechanical properties.5,6 Both
TGF-b and MMP-2 and MMP-9 are therefore believed to
be crucial molecular mediators in the pathogenesis of310 The Journal of Thoracic and Cardiovascular SurgMarfan syndrome. This study has extended our previous
findings and is the first to demonstrate the beneficial effects
of losartan potassium and doxycycline in the secondary
prevention of TAA in Marfan syndrome. There are 3 novel
findings in this study: (1) Neither losartan potassium nor
doxycycline alone could completely restore vascular integ-
rity and cell function when given during the delayed treat-
ment, indicating the importance of timed pharmacologic
intervention. (2) During the delayed treatment, losartan
potassium effectively improved aortic contractility, whereas
doxycycline improved endothelium-dependent relaxation.
(3) The combination of losartan potassium and doxycycline
offered more beneficial effects than either single-drug
therapy in improving elastic fiber organization, normalizing
vasomotor function, inhibitingMMP-2,MMP-9, and TGF-b
activation, and, most importantly, reducing the size of
aneurysm throughout the life span.
The secondary prevention study indicated the importance
of the timing of pharmacologic intervention. We examinedery c August 2010
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sium once the process of aneurysmal degeneration had
already become established. Our results indicated that even
delayed treatment with either medication reduced aortic dila-
tation and improved elastic fiber architecture. Additionally,
losartan potassium appeared to offer better contractile
response andMMPandTGF-b inhibitions and caused amod-
erate improvement in breaking stress, whereas doxycycline
yielded better relaxation response and breaking stress thresh-
old. This finding further supports the rationale for combined
therapy.We have previously shown that the disruption of the
MMP/TIMP balance could be associated with the excessive
elastic fiber degradation in TAA.5,6 The remarkable reduc-
tion in MMP/TIMP ratios produced by losartan potassium
both alone and in combinationwith doxycycline thus suggest
that proteolytic activity in the vasculature and vascular
remodeling during aortic dilatation could be reduced by these
treatments. Furthermore, the normalization of the elastic fiber
architecture by the combined treatment could contribute to
the favorably increased breaking stress threshold, which is
implicated in the reduced incidences of aortic dilatation, dis-
section, and rupture. During aging, the reduction of breaking
stress in the control group demonstrates the detrimental
effects of aging on vascular mechanical properties.
In the development of aneurysm, the increased proteinase-
mediated TGF-b release could reinforce the proposed vicious
cycle.6 We demonstrated that the losartan potassium both
alone and in combination with doxycycline was effective in
downregulatingMMP activation in the secondary prevention.
We previously reported the aneurysm-suppressing effects of
doxycycline through the inhibition of MMP-2 and MMP-9,5
and the lack of inhibition of MMP expression in this study
may have been due to the delayed intervention. The cross
talk between MMP and TGF-b has been extensively docu-
mented. TGF-b overexpression and its downstream signaling
(TGF-b receptor/Smad) are associated with MMP upregula-
tion at the transcriptional and translational levels, and MMP-
2 and MMP-9 have been identified as TGF-b activators.11-16
Within the aortic wall during aging, TGF-b activation is de-
pendent on the age-associated increase in MMP-2 activity.15
Overexpression of TGF-b and the concomitant upregulation
of MMPs and TIMPs are associated with increased apoptosis,
impaired progenitor cell recruitment, and abnormal directional
migration, all of which are likely to contribute to aneurysmal
development in Marfan syndrome.11,12 Increased TGF-b sig-
naling could cause valve calcification and dysfunction through
the apoptotic events and increase in MMP-9.16 The homozy-
gote dura stained for expression of activated TGF-b and
MMP-2 suggested that dural ectasia in MFS may be due to
TGF-b overactivation and to MMP-2–mediated elastolysis
and collagen breakdown.13
Although in the delayed treatment neither losartan potas-
sium nor doxycycline alone fully prevented vascular remodel-
ing and cellular dysfunction, their combination greatlyThe Journal of Thoracic and Caenhanced the beneficial effects of single-drug therapy by
improving the aortic contractility and endothelium-dependent
relaxation. The significant improvement in aortic contractility
with the combined and losartan potassium–alone treatments
could be explained by the normalization of elastic fiber integ-
rity. It has been shown that growing smooth muscle cells on
elastin preserves the contractile phenotype, as demonstrated
by the presence of contractile myofilaments, and that mice
deficient in elastin would develop less contractile force.17
According to ultrastructural analysis, elastic laminae connect
to adjacent endothelial and smoothmuscle cells through an in-
termediate structure composed of microfibrils.18 It has been
shown that the arginine–glycine–aspartic acid sequence of
fibrillin-1 can support cellular adhesion through integrin
a5b3, and these interactions are believed to contribute to the
vascular structural integrity and to coordinate contractile and
elastic tensions.19 Second, during the combined and the losar-
tan potassium–alone treatment, the pronounced reduction of
MMP could improve the contractility, because increased
levels of MMP-2 and MMP-9 are associated with impaired
contraction.5,6,20 Nevertheless, TGF-b has been demonstrated
to impair vasoconstriction directly. In mouse cerebral artery,
high TGF-b concentration inhibited endothelin-1–induced
contraction by inducing mitogen-activated protein kinase
phosphatase 1.21 TGF-b could cause vascular dysfunction of
early diabetes by inhibiting calcium transients and impairing
angiotensin II–induced contraction.22
Although losartan potassiumexerted pronouncedbeneficial
effects on aortic contractile function, it only moderately im-
proved the endothelium-dependent relaxation. Through the
transcriptional activation of the endothelial nitric oxide syn-
thase gene promoter, TGF-b and the downstream nuclear
translocation of Smad-2 increase endothelial nitric oxide syn-
thase expression and nitric oxide production in endothelial
cells.23 Low blood level of TGF-b is associated with the path-
ogenesis of atherosclerosis, vascular hypertrophy, and the se-
verity of vascular disease.24 It is widely believed that nitric
oxidemediates vasorelaxation, but it also regulates the balance
of vascular smooth muscle cell proliferation and apoptosis,
governing important aspects of vessel caliber and remodel-
ing.25 The endothelial dysfunction during the losartan potas-
sium treatment at 9 months of age thus may exert negative
effects on vascular health andmay be associatedwith aberrant
vascular remodeling. Endothelial function could, however, be
effectively enhanced with doxycycline. We have previously
reported that doxycycline normalizes the endothelium-depen-
dent relaxation and the basal nitric oxide level, coincidentwith
the upregulation of endothelial nitric oxide synthase phos-
phorylation.5-7 It is worthy ofmention that aging caused endo-
thelial dysfunction in both wild-type and untreated groups,
which might mask the vascular pathogenesis of the disease.
Aortas treatedwith doxycycline either alone or in combination
with losartan potassium, however, exhibited better endothelial
function even than the control.rdiovascular Surgery c Volume 140, Number 2 311
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diameter was assessed from the histologic slides rather than
in vivo imaging, and this assessment does not allow the true
measurement of the embedded aortic root. Lack of the in
vivo longitudinal examination on aortic diameter does not
allow us to confirm that either losartan potassium or doxycy-
cline treatment offers aneurysm-suppressing benefits
through the life span of the animal. This histologic assess-
ment may also underestimate the difference in diameter.
The differences in aortic diameter presented here might be
more pronounced if we had performed in vivo measure-
ments. Our results thus raise interesting questions for further
testing with more sophisticated and appropriate methodol-
ogy. Second, all functional experiments were performed
on the aortic arch, but not the ascending part because of its
very short length. We used the aortic arch protein in the mo-
lecular biology experiments, and the limited ascending aorta
was fixed for histologic examination. Although most of the
aneurysms in human patients with Marfan syndrome are
seen in the aortic root and ascending aorta, our preliminary
data and previous publications have shown that similar
disease pathogenesis and aberrant signaling pathways are
exhibited in the ascending aorta and the arch.5-7 Third, there
are more than 600 mutations identified in Marfan syn-
drome.1 Whereas missense mutations account for 60% of
the mutations, 78% of the point mutations are located in
the collagen-binding epidermal growth factor (CBEGF)
modules. A further 12% of these mutations are recurrent
and affect a CpG mutation hotspot for a cysteine residue.1
This type of mutation is the basis of the mouse model
used in this study and represents the most common mutation
in classic Marfan syndrome.8 We therefore find that al-
though our model is useful to investigate the general patho-
genesis of Marfan syndrome, it may not be representative of
all cases of Marfan syndrome in human beings.
In conclusion, we are the first to show that delayed treat-
ment greatly reduces the effectiveness of single therapy with
either losartan potassium or doxycycline, implicating the im-
portance of timed pharmacologic intervention. In contrast,
combined therapy with losartan potassium and doxycycline
not only offered superior aneurysm protection but also im-
proved vascular cell function and elastic fiber structural
properties. Our study offers better understanding of optimal
treatment for Marfan syndrome, which is important to lessen
the risks of aortic dilatation, dissection, and rupture, and to
reduce the associated morbidity and mortality.
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Appendix E1. Additional Detail for Materials and
Methods
Movat Staining
Aortic segments were formalin fixed and embedded in paraf-
fin. Because of the limited samples from each mouse, perfu-
sion fixation was not performed. From each aortic sample, 3
cross-sections (3 mm) were cut from the proximal end,
prepared, and stained with modified Movat pentachrome.
To ensure consistency and reproducible histologic proce-
dures, all samples were fixed, cut, mounted, and stained by
the same technician in the department of pathology. Image
acquisition and processing were performed with a NikonMi-
croPhot microscope (Nikon Instruments Inc, Melville, NY).
Each slide was examined by 3 observers from the department
of pathology who were blinded to genotype and treatment.
On each slide, 8 regions were examined (0, 45, 90,
135, 180, 225, 270, 315) and given a score on a scale
from 1 to 4 as follows: 1, extensive fragmentation and degra-
dation; 2, local degradation and fragmentation; 3, mild disor-
ganization without fragmentation; 4, completely intact with
wavy organization.1-4 Aortic wall architecture score was
averaged from these 8 regions, from 3 slides and 3 observers
each. Lumen diameter was calculated assuming circular
geometry as the inner vessel circumference divided by p.
Gelatinolytic Zymography
The procedures for gelatinolytic zymography have been
extensively described in our previous publications.1,2,4,5
Briefly, aortic segments were ground with liquid nitrogen
in a stainless-steel mortar and pestle. Tissue powder was
mixed in 9 volumes of ice-cold lysis buffer (50-mmol/L
tris[hydroxymethyl]aminomethane [Tris] hydrochloride,
pH 7.4, with 3.1-mmol/L sucrose, 1-mmol/L dithiothreitol,
10-mg/mL leupeptin, 10-mg/mL soybean trypsin inhibitor,
2-mg/mL aprotinin, and 0.1% Triton X-100 [The Dow
Chemical Company, Midland, Mich]). After 20 minutes of
incubation on ice, samples were homogenized with a glass
homogenizer. The gelatinolytic activity was analyzed by
separating protein (10 mg) on 8% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis gels copolymerized
with gelatin (2 mg/mL) as substrate. After electrophoresis,
the gels were washed with 2.5% Triton X-100 and then in-
cubated in incubation buffer (50-mmol/L Tris hydrochloride
buffer with 0.15-mol/L sodium chloride, 5-mmol/L calcium
chloride, and 0.05% sodium azide, pH 7.4) at 37C until ac-
tivities of the enzymes could be determined. After incuba-
tion, the gels were stained with 0.05% Coomassie brilliant
blue G-250 in a mixture of methanol/acetic acid/water
(2.5:1:6.5) and destained in 4% methanol with 8% acetic
acid. The gelatinolytic activity was identified as transparent
bands against the background of Coomassie blue–stained
gelatin. Images were taken with a Canon digital camera
(Canon U.S.A., Inc, Lake Success, NY), and densitometry
was analyzed with Quality One Image software (Bio-Rad
Laboratories, Inc, Hercules, Calif).
Western Immunoblotting
Because of the limited sample from eachmouse, aortic arch
samples were pooled in groups with the same strain and age.
Procedures of Western blotting were previously described.1-7
After homogenization, protein concentration was determined
by Bradford reagent with bovine serum albumin as standards
(Bio-Rad). Protein extracts (20 mg) were diluted to the equiv-
alent amounts of total protein per sample in sample buffer con-
taining 40% glycerol, 8% sodium dodecyl sulfate, 0.5-mol/L
Tris hydrochloride (pH 6.8), 0.02% bromophenol blue, and
4% b-mercaptoethanol. Samples were then subjected to 8%
(for MMP-2 and MMP-9) or 13% (for TIMP-1 and TIMP-
2), then transferred to polyvinyldifluoride membranes
(Bio-Rad).Membranes were blocked overnight with blocking
buffer (5% nonfat dry milk in Tris-buffered saline solution
containing 0.1% polysorbate 20) and then probed with anti–
MMP-2 and anti–MMP-9 antibodies (Siemens Healthcare
Diagnostics Inc, Oncogene Science, Cambridge, Mass) and
mouse monoclonal anti–TIMP-1 and anti–TIMP-2 antibodies
(EMDChemicals Inc, Gibbstown,NJ) overnight at 4C.After
washing 3 times in Tris-buffered saline solution containing
0.1% polysorbate 20, membranes were incubated with anti–
mouse IgGperoxidase-conjugated secondary antibodies (dilu-
tion 1:2500) for 1 hour. The immunoreactive proteins were
then visualized by chemiluminescence (GE Healthcare Life
Sciences, Little Chalfont, UK), and densitometric measure-
ment was performed. To ensure equal protein loading, mem-
branes were stripped by incubating in 62.5-mmol/L Tris
hydrochloride (pH 6.8), 1% sodium dodecyl sulfate, and
100-mmol/L b-mercaptoethanol at 55C and reprobed with
anti–b-actin mouse antibody (dilution 1:5000).1-7
Mechanical Properties of Aorta
Vessel elasticity was deduced from the stress–strain expo-
nential curves.1,2,8 The procedure was repeated until the ves-
sel was unable to maintain its resting tension. The stress at
which instability occurred was reported as breaking stress.
The stress–strain relationship was graphed as J-shaped
curves. Equation of the exponential growth was Y ¼ Start
$ exp(K $ X), where Y is stress, X is strain, and K is a rate
constant at which Y increases exponentially. Increased K
value indicates increased stiffness.
Isometric Force Measurement
Aortic arch (uncurved part, 1.8mm in length) wasmounted
on two 40-mm diameter stainless steel wires isometrically in
a small-vessel myograph (DMT A/S, N Aarhus, Denmark)
for the measurement of the generated force. Vessel segments
were stretched for 30 minutes, at which time the resting force
was stabilized, then challenged with 60-mmol/L potassium
chloride. To evaluate the endothelium-dependent relaxation,
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vessels were precontracted with 3-mmol/L phenylephrine be-
fore addition of acetylcholine (0.01 nmol/L–100 mmol/L).
Concentration–response curves of phenylephrine-induced
contraction and acetylcholine-induced relaxation were
constructed. The negative logarithm of the concentration of
acetylcholine yielding half maximum response was assessed
by linear interpolation on the semilogarithm concentration-
response curve, pEC50 ¼ log(EC50), so that EC50 is the
50% effective concentration and pEC50 is its negative
logarithm.1,2,6,7,8
Materials
All other reagents were of the highest molecular grade,
purchased from Sigma (Sigma-Aldrich Canada Ltd,
Oakville, Ontario, Canada).
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